Beta Bionics (NASDAQ:BBNX – Get Free Report) and Jushi (OTCMKTS:JUSHF – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Earnings and Valuation
This table compares Beta Bionics and Jushi”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beta Bionics | $100.25 million | 9.08 | -$73.20 million | ($1.84) | -9.10 |
| Jushi | $262.91 million | 0.32 | -$68.59 million | ($0.28) | -1.48 |
Jushi has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Jushi, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Beta Bionics has a beta of 3.39, meaning that its stock price is 239% more volatile than the S&P 500. Comparatively, Jushi has a beta of -0.62, meaning that its stock price is 162% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and target prices for Beta Bionics and Jushi, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beta Bionics | 1 | 4 | 9 | 1 | 2.67 |
| Jushi | 0 | 0 | 1 | 0 | 3.00 |
Beta Bionics currently has a consensus target price of $23.69, indicating a potential upside of 41.45%. Given Beta Bionics’ higher possible upside, research analysts plainly believe Beta Bionics is more favorable than Jushi.
Institutional and Insider Ownership
21.7% of Jushi shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 23.1% of Jushi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Beta Bionics and Jushi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beta Bionics | -65.31% | -27.33% | -24.28% |
| Jushi | -19.98% | N/A | -12.91% |
Summary
Jushi beats Beta Bionics on 10 of the 15 factors compared between the two stocks.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
About Jushi
Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
